Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Directorate Change

14 Dec 2012 07:00

RNS Number : 5188T
Immunodiagnostic Systems Hldgs PLC
14 December 2012
 



14 December 2012

 

Immunodiagnostic Systems Holdings plc

 

Chris Yates appointed as Group Finance Director

 

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces that Chris Yates has been appointed Group Finance Director, with effect from 4th March 2013. 

 

Chris Yates, aged 38, joins IDS from private equity backed Nexus Vehicle Holdings Limited, where he has acted as Group Finance Director since January 2009. During his time at Nexus, as well as holding overall responsibility for finance and human resources, Chris oversaw the acquisition of Adapted Vehicle Hire Limited in May 2010.

 

From 2005 to 2007, Chris held the position of Group Finance Director at Cozart plc, allowing him to gain significant experience in the medical diagnostics industry.  During his time at Cozart, Chris led the acquisitions of four European companies: Spinreact SA (Spain), HL Scandinavia (Sweden), Nemesis Scientific Limited (UK) and Medib Skandinavien AB (Sweden) creating a pan-European medical diagnostics group. Cozart was subsequently acquired by Concateno plc (now part of Alere Inc.) in October 2007 for £64m in cash.

 

In 2008 Chris then furthered his industry expertise by acting as Co-founder and Finance Director of private specialist diagnostics company, Abingdon Health Limited.

 

From 4th March 2013 Barry Hextall, currently interim Group Finance Director, will resume his previous role as Deputy Group Finance Director.

 

Patrik Dahlen, Chief Executive Officer of IDS, commented: "It is a pleasure to announce that Chris Yates will be joining our team as Group Finance Director. As well as having a strong financial background, I am confident that Chris's knowledge and experience in the diagnostics industry will prove to be invaluable to IDS during this crucial time in the evolution of the business as a leading innovator and provider of specialist assays and diagnostic testing kits.

 

"I would also like to thank Barry Hextall for his continued support as Interim Finance Director."

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Patrik Dahlen, Chief Executive Officer

 

 

 

 

 

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

 

Dr Vijay Barathan

 

 

 

FTI Consulting

Tel : +44 (0)207 831 3113

Ben Atwell

 

Simon Conway

 

Mo Noonan

 

 

 

Additional Information

Christopher Henry Francis Yates (aged 38) currently holds and has held (including all appointments during the five years preceding the date of this announcement), the following directorships and partnerships, other than the Company:

 

Current directorships:

Adapted Vehicle Hire Limited

Forsite Diagnostics Limited

Nexus VRM Limited

Nexus Vehicle Management Ltd

Nexus Vehicle Holdings Limited

Abingdon Health LTD

 

Chris currently has no shares in the Company and there are no other disclosures required pursuant to Rule 17 and Schedule 2; paragraph (g) of the AIM Rules for Companies.

 

About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.

 

http://www.idsplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGQGPUPPPWW
Date   Source Headline
1st Jun 20117:00 amRNSAppointment of Non-Executive Director
9th May 20117:00 amRNSChange of contract terms
28th Apr 20117:00 amRNSTotal Voting Rights
12th Apr 20118:34 amRNSExercise of Share Options and Total Voting Rights
6th Apr 20117:00 amRNSTrading update
28th Mar 20117:35 amRNSExclusive Licence Agreement
1st Mar 20117:00 amRNSDirector/PDMR Shareholding
3rd Feb 201110:34 amRNSDirector/PDMR Shareholding
11th Jan 20113:40 pmRNSDirector/PDMR Shareholding
30th Nov 20107:00 amRNSHalf Yearly Report
12th Nov 20104:41 pmRNSSecond Price Monitoring Extn
12th Nov 20104:35 pmRNSPrice Monitoring Extension
1st Nov 201011:22 amRNSHolding(s) in Company
5th Oct 20108:56 amRNSPosting of Report and Accounts and Notice of AGM
5th Oct 20107:00 amRNSTrading Update
27th Sep 20107:00 amRNSIssue of Equity
21st Sep 20104:35 pmRNSPrice Monitoring Extension
20th Sep 201010:33 amRNSHolding(s) in Company
13th Sep 20107:00 amRNSAcquisition & Research Agreement
25th Aug 20104:06 pmRNSResult of AGM
25th Aug 20107:00 amRNSAGM Statement
26th Jul 20101:00 pmRNSExercise of Share Options and Total Voting Rights
26th Jul 20107:00 amRNSNew specialist assay launched for IDS-iSYS
20th Jul 20107:00 amRNSDirector/PDMR Shareholding
12th Jul 20107:00 amRNSDirectorate Change
12th Jul 20107:00 amRNSFinal Results
29th Jun 20107:00 amRNSReceipt of FDA 510(k) clearances
16th Jun 20104:40 pmRNSSecond Price Monitoring Extn
16th Jun 20104:35 pmRNSPrice Monitoring Extension
14th Jun 20104:35 pmRNSPrice Monitoring Extension
11th Jun 20104:35 pmRNSPrice Monitoring Extension
10th Jun 20104:35 pmRNSPrice Monitoring Extension
26th May 20104:40 pmRNSSecond Price Monitoring Extn
26th May 20104:35 pmRNSPrice Monitoring Extension
10th May 20107:00 amRNSExercise of Share Options
12th Apr 20107:00 amRNSTrading Statement
31st Mar 201012:24 pmRNSTotal Voting Rights
31st Mar 20107:00 amRNSNew specialist assays launched for IDS-iSYS
22nd Mar 20107:00 amRNSDirector/PDMR Shareholding
16th Mar 201010:00 amRNSDirector/PDMR Shareholding
23rd Feb 201011:47 amRNSExercise of Share Options
9th Feb 20107:00 amRNSShare options
1st Feb 20109:13 amRNSExercise of Share Options and Total Voting Rights
4th Jan 20107:00 amRNSFive year distribution agreement
21st Dec 20091:15 pmRNSDirector/PDMR Shareholding
18th Dec 20093:18 pmRNSIssue of Equity
11th Dec 20097:00 amRNSDirectorate Change
10th Dec 20097:00 amRNSExercise of Share Options and Directors' Dealings
30th Nov 20097:00 amRNSHalf Yearly Report
18th Nov 200910:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.